Cost-Effectiveness of New Diagnostic Tools and Therapies for Acute Coronary Syndromes

Acute Coronary Syndromes, Third Edition: Revised and Expanded

Volumn , Issue , 2004, Pages 723-745

  Eisenstein, Eric L ^a   Mark, Daniel B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 17244369924     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780203025673-34     Document Type: Chapter

References (133)

1. Getzen TE. Health economics: fundamentals and flow of funds. New York: John Wiley & Sons, 1997.
2. CDC Faststats A-Z. Centers for Disease Control National Center for Health Statistics, 2003.
3. Jacobs E, Shipp S. How family spending has changed in the United-States. Mon Labor Rev 1990;113:20-27.
4. Eisenstein EL, Peterson ED, Jollis JG, Tardiff BE, Califf RM, Knight JD, Mark DB. Evaluating the potential ‘economic attractiveness’ of new therapies in patients with non-ST elevation acute coronary syndrome. Pharmacoeconomics 2000;17:263-272.
5. Health United States 1998. Health Care Financing Administration. In: http://www.cdc.gov/nchs/fastats/pdf/hu98t119.pdf. Accessed March 06, 2000.
6. Day HW. An intensive coronary care area. Dis Chest 1963;44:423-427.
7. Koch EB, Reiser SJ. Critical care: historical development and ethical considerations. In: Fein IA, Strosbers MA, Eds. Managing the clinical care unit. Rockville. MD: Aspen, 1987:3-20.
8. Hilberman M. The evolution of intensive care units. Crit Care Med 1975;3:159-165.
9. Reiser SJ. The intensive care unit. The unfolding ambiguities of survival therapy. Int J Technol Assess Health Care 1992;8:382-394.
10. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, Grinfeld L, Gibbons RJ, Ribeiro EE, DeWood MA, Ribichini F. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997;278:2093-2098.
11. The ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716-722.
12. Nagle TT, Holden RK. The strategy and tactics of pricing: a guide to profitable decision making, Upper Saddle River, Prentice Hall. 2002.
13. Mark DB, Topol EJ. Chronic coronary artery disease. In: Talley JD, Mauldin PD, Becker ER, Eds. Cost effective diagnosis and treatment of coronary artery disease. Baltimore. MD:Williams & Wilkins, 1997:168-177.
14. Califf RM, Eisenstein EL. Cost-effectiveness of therapy for acute ischemic heart disease. In:Talley JD, Ed. Cost-effective diagnosis and treatment of coronary artery disease, Igaku-Shoin. 1997:139-167.
15. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term '‘cost effective’' in medicine. N Engl J Med 1986;314:253-256.
16. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-1151.
17. US Renal Data System. USRDS 2002 Annual Data Report. Bethesda, MD: NIH, National Institutes of Diabetes and Digestive and Kidney Diseases, 2002.
18. Mark DB. Medical economics in cardiovascular medicine. In: Topol EJ, Ed. Textbook of cardiovascular medicine. New York. NY: Lippincott-Raven, 1997:1033-1062.
19. Hadorn DC. Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue. JAMA 1991;265:2218-2225.
20. Eddy DM. Oregon’s methods. Did cost-effectiveness analysis fail? JAMA 1991;266:2135-2141.
21. Leichter HM. Oregon’s bold experiment: whatever happened to rationing? J Health Polit Policy Law 1999;24:147-160.
22. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. Br Med J 1993;306:570-572.
23. Glassman PA, Model KE, Kahan JP, Jacobson PD, Peabody JW. The role of medical necessity and cost-effectiveness in making medical decisions. Ann Intern Med 1997;126:152-156.
24. Finkler SA. Cost accounting for health care organizations. Rockville. MD: Aspen Publishers, 1994.
25. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York. NY: Oxford University Press, 1996.
26. Lipscomb J, Mark DB, Cowper PA. Comparison of hospital costs derived from cost-to-charge ratios and from a detailed cost accounting system for patients undergoing cardiac procedures. Associated Health Services Research Conference, 1994.
27. Ashby JL. The accuracy of cost measures derived from Medicare cost report data. Hospital (Rio J) 1992;3:1-8.
28. Barnett PG. Research without billing data. Econometric estimation of patient-specific costs. Med Care 1997;35:553-563.
29. Eisenstein EL, Shaw LK, Anstrom KJ, Nelson CL, Hakim Z, Hasselblad V, Mark DB. Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med Care 2001;39:824-35.
30. Detsky AS. Using cost-effectiveness analysis for formulary decision making: from theory into practice. Pharmacoeconomics 1994;6:281-288.
31. Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients’ well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992; 45:505-512.
32. Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: what is a clinically significant gain? J Gen Intern Med 1994;9:702-7.
33. Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991; 83:1194-1201.
34. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions--standardizing data on outcomes. N Engl J Med 1998;339:380-386.
35. Barish RA, Doherty RJ, Browne BJ. Reengineering the emergency evaluation of chest pain. J Healthc Qual 1997;19:6-12.
36. National Center for Health Statistics. National Hospital Ambulatory Medical Care Survey:1995 Emergency Department Survey. Advance data from vital health statistics. Hyattsville. MD: Public Health Service, 1997.
37. The DRG handbook: comparative clinical and financial standards. Baltimore. MD: HCIA, 1997.
38. Newby LK, Gibler WB, Christenson RH, Ohman EM. Serum markers for diagnosis and risk stratification in acute coronary syndromes. In: Cannon CP, Ed. Contemporary cardiology:management of acute coronary syndromes. Totowa. NJ: Humana Press Inc, 1998:147-217.
39. Jesse RL, Kontos MC. Evaluation of chest pain in the emergency department. Curr Probl Cardiol 1997;22:149-236.
40. Farkouh ME, Smars PA, Reeder GS, Zinsmeister AR, Evans RW, Meloy TD, Kopecky SL, Allen M, Allison TG, Gibbons RJ, Gabriel SE. A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators. N Engl J Med 1998;339:1882-1888.
41. Gomez MA, Anderson JL, Karagounis LA, Muhlestein JB, Mooers FB. An emergency department- based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: results of a randomized study (ROMIO). J Am Coll Cardiol 1996;28:25-33.
42. Gaspoz JM, Lee TH, Weinstein MC, Cook EF, Goldman P, Komaroff AL, Goldman L. Costeffectiveness of a new short-stay unit to '‘rule out’' acute myocardial infarction in low risk patients. J Am Coll Cardiol 1994;24:1249-1259.
43. Mikhail MG, Smith FA, Gray M, Britton C, Frederiksen SM. Cost-effectiveness of mandatory stress testing in chest pain center patients. Ann Emerg Med 1997;29:88-98.
44. Roberts RR, Zalenski RJ, Mensah EK, Rydman RJ, Ciavarella G, Gussow L, Das K, Kampe LM, Dickover B, McDermott MF, Hart A, Straus HE, Murphy DG, Rao R. Costs of an emergency department-based accelerated diagnostic protocol vs. hospitalization in patients with chest pain: a randomized controlled trial. JAMA 1997;278:1670-1676.
45. Newby LK, Califf RM. Identifying patient risk: the basis for rational discharge planning after acute myocardial infarction. J Thromb Thrombolysis 1996;3:107-115.
46. Braunwald E, Mark DB, Jones RHet al. Unstable angina: diagnosis and management.Agency for Health Care Policy and Research. Pamphlet _94-0682. Rockville. MD: U.S. Department of Health and Human Services, 1994.
47. Katz DA, Griffith JL, Beshansky JR, Selker HP. The use of empiric clinical data in the evaluation of practice guidelines for unstable angina. JAMA 1996;276:1568-1574.
48. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2000;102:1193-1209.
49. Green GB, Beaudreau RW, Chan DW, DeLong D, Kelley CA, Kelen GD. Use of troponin T and creatine kinase-MB subunit levels for risk stratification of emergency department patients with possible myocardial ischemia. Ann Emerg Med 1998;31:19-29.
50. Tucker JF, Collins RA, Anderson AJ, Hauser J, Kalas J, Apple FS. Early diagnostic efficiency of cardiac troponin I and Troponin T for acute myocardial infarction. Acad Emerg Med 1997; 4:13-21.
51. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337:1648-1653.
52. Collinson PO. Troponin T or troponin I or CK-MB (or none?). Eur Heart J 1998;19(Suppl N):N16-N24.
53. Heeschen C, Hamm CW, Goldmann BU, Moeller RH, Meinertz T. [Cost-effectiveness of a rapid test for troponin in emergency admissions]. Dtsch Med Wochenschr 1998;123:1229-1234.
54. Anderson FP, Fritz ML, Kontos MC, McPherson RA, Jesse RL. Cost-effectiveness of cardiac troponin I in a systematic chest pain evaluation protocol: use of cardiac troponin I lowers length of stay for low-risk cardiac patients. Clin Lab Manage Rev 1998;12(2):63-69.
55. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:1418-1424.
56. 1994 drug topics red book. Montvale. NJ: Medical Economics Data, 1994.
57. Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, Simes J, Dalby A, Betriu A, Bode C, White HD, Hochman JS, Emanuelson H, Vahanian A, Sapp S, Stebbins A, Moliterno DJ, Califf RM. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Circulation 2000; 102:1761-1765.
58. Mark DB. Ecomomics of therapy for acute coronary syndromes. In: Weintraub WS, Ed. Cardiovascular health care economics. Totowa. NJ: Humana Press, 2003:173-185.
59. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-1914.
60. The ASSENT 3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
61. Kaul P, Armstrong PW, Cowper PA, Eisenstein EL, Granger CB, Van de Werf F, Mark DB. Economic analysis of the assessment of the ssafety and efficacy of a new thrombolytic regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. Am Heart J 2004:in press.
62. Reeder GS, Bailey KR, Gersh BJ, Holmes DR, Christianson J, Gibbons RJ. Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Coronary Care Unit and Catheterization Laboratory Groups. Mayo Clin Proc 1994;69:5-12.
63. de Boer MJ, van Hout BA, Liem AL, Suryapranata H, Hoorntje JC, Zijlstra F. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. Am J Cardiol 1995;76:830-833.
64. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.
65. Stone GW, Grines CL, Rothbaum D, Browne KF, O’Keefe J, Overlie PA, Donohue BC, Chelliah N, Vlietstra R, Catlin T, O’Neill WW. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. J Am Coll Cardiol 1997; 29:901-907.
66. Beatt KJ, Fath-Ordoubadi F. Angioplasty for the treatment of acute myocardial infarction. Heart 1997;78(Suppl 2):12-15.
67. Lieu TA, Gurley RJ, Lundstrom RJ, Ray GT, Fireman BH, Weinstein MC, Parmley WW. Projected cost-effectiveness of primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1997;30:1741-1750.
68. Grines CL, Westerhausen DR, Grines LL, Hanlon JT, Logemann TL, Niemela M, Weaver WD, Graham M, Boura J, O’Neill WW, Balestrini C. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction:the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002; 39:1713-1719.
69. Andersen HR, Nielsen TT, Vesterlund T, Grande P, Abildgaard U, Thayssen P, Pedersen F, Mortensen LS. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2). Am Heart J 2003;146:234-241.
70. Cannon CP, Baim DS. Expanding the reach of primary percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol 2002;39:1720-1722.
71. Le May MR, Labinaz M, Davies RF, Marquis JF, Laramee LA, O’Brien ER, Williams WL, Beanlands RS, Nichol G, Higginson LA. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol 2001;37:985-991.
72. Le May MR, Davies RF, Labinaz M, Sherrard H, Marquis JF, Laramee LA, O’Brien ER, Williams WL, Beanlands RS, Nichol G, Higginson LA. Hospitalization costs of primary stenting versus thrombolysis in acute myocardial infarction: cost analysis of the Canadian STAT Study. Circulation 2003;108:2624-2630.
73. Steinhubl SR, Topol EJ. Stenting for acute myocardial infarction. Lancet 1997;350:532-533.
74. Suryapranata H, van’t Hof AW, Hoorntje JC, de Boer MJ, Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 1998;97:2502-2505.
75. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O’Neill WW, Morice MC. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999;341:1949-1956.
76. van ‘t Hof AW, Suryapranata H, de Boer MJ, Hoorntje JC, Zijlstra F. Costs of stenting for acute myocardial infarction. Lancet 1998;351:1817.
77. Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW, Grines CL. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation 2001;104:3039-3045.
78. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ. Randomized, placebocontrolled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-741.
79. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.
80. The ADMIRAL Investigators:Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med, 2001.
81. Bakhai A, Stone GW, Grines CL, Murphy SA, Githiora L, Berezin RH, Cox DA, Stuckey T, Griffin JJ, Tcheng JE, Cohen DJ. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. Circulation 2003;108:2857-2863.
82. Krumholz HM. Cost-effectiveness analysis and the treatment of acute coronary syndromes. In: Cannon CP, Ed. Contemporary cardiology: management of acute coronary syndromes. Totowa. NJ: Human Press, 1998:601-610.
83. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 1996;94:911-921.
84. Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation 1998;98:287-289.
85. The GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996;335:775-782.
86. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452.
87. Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AG, Califf RM, Weatherley B, Cohen M. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Circulation 1998;97:1702-1707.
88. Fox KA. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials. Am J Cardiol 1999;84:26M-31M.
89. McElwee NE, Johnson ER. Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes. Am J Cardiol 1997; 80:39B-43B.
90. Szucs TD, Meyer BJ, Kiowski W. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. Eur Heart J 1999;20:1253-1260.
91. Mark DB, Harrington RA, Lincoff AM, Califf RM, Nelson CL, Tsiatis AA, Buell H, Mahaffey KW, Davidson-Ray L, Topol EJ. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000;101:366-371.
92. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-443.
93. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329-1339.
94. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
95. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800-1806.
96. Lindgren P, Jonsson B. Modeling the cost effectiveness of clopidogrel in acute coronary syndromes without ST-segment elevation in Sweden. J Am Coll Cardiol 2003;41:540A.
97. Calvin JE, Klein LW, VandenBerg BJ, Meyer P, Condon JV, Snell RJ, Ramirez-Morgen LM, Parrillo JE. Risk stratification in unstable angina. Prospective validation of the Braunwald classification. JAMA 1995;273:136-141.
98. Braunwald E. Unstable angina. A classification. Circulation 1989;80:410-414.
99. Calvin JE, Klein LW, VandenBerg BJ, Meyer P, Ramirez-Morgen LM, Parrillo JE. Clinical predictors easily obtained at presentation predict resource utilization in unstable angina. Am Heart J 1998;136:373-381.
100. Spertus JA, Weiss NS, Every NR, Weaver WD. The influence of clinical risk factors on the use of angiography and revascularization after acute myocardial infarction. Myocardial Infarction Triage and Intervention Project Investigators. Arch Intern Med 1995;155:2309-2316.
101. Mark DB. Implications of cost in treatment selection for patients with coronary heart disease. Ann Thorac Surg 1996;61:S12-S15.
102. Wennberg DE, Kellett MA, Dickens JD, Malenka DJ, Keilson LM, Keller RB. The association between local diagnostic testing intensity and invasive cardiac procedures. JAMA 1996;275:1161-1164.
103. Guadagnoli E, Hauptman PJ, Ayanian JZ, Pashos CL, McNeil BJ, Cleary PD. Variation in the use of cardiac procedures after acute myocardial infarction. N Engl J Med 1995;333:573-578.
104. Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, Gore JM, Armstrong PW, Ohman EM, Topol EJ. Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med 1995;333:565-572.
105. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA 1994; 272:859-866.
106. Marrugat J, Sanz G, Masia R, Valle V, Molina L, Cardona M, Sala J, Seres L, Szescielinski L, Albert X, Lupon J, Alonso J. Six-month outcome in patients with myocardial infarction initially admitted to tertiary and nontertiary hospitals. RESCATE Investigators. Recursos Empleados en el Sindrome Coronario Agudo y Tiempos de Espera. J Am Coll Cardiol 1997; 30:1187-1192.
107. Gatsonis CA, Epstein AM, Newhouse JP, Normand SL, McNeil BJ. Variations in the utilization of coronary angiography for elderly patients with an acute myocardial infarction. An analysis using hierarchical logistic regression. Med Care 1995;33:625-642.
108. Every NR, Fihn SD, Maynard C, Martin JS, Weaver WD. Resource utilization in treatment of acute myocardial infarction: staff-model health maintenance organization versus fee-forservice hospitals. The MITI Investigators. Myocardial Infarction Triage and Intervention. J Am Coll Cardiol 1995;26:401-406.
109. Pilote L, Miller DP, Califf RM, Rao JS, Weaver WD, Topol EJ. Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med 1996;335:1198-1205.
110. van Miltenburg-van Zijl AJ, Simoons ML, Bossuyt PM, Taylor TR, Veerhoek MJ. Variation in the use of coronary angiography in patients with unstable angina is related to differences in patient population and availability of angiography facilities, without affecting prognosis. Eur Heart J 1996;17:1828-1835.
111. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89:1545-1556.
112. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy). Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
113. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002;288:1851-1858.
114. Newby LK, Califf RM, Guerci A, Weaver WD, Col J, Horgan JH, Mark DB, Stebbins A, Van de Werf F, Gore JM, Topol EJ. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. J Am Coll Cardiol 1996;27:625-632.
115. Newby LK, Califf RM. Identifying patient risk: the basis for rational discharge planning after acute myocardial infarction. J Thromb Thrombolysis 1996;3:107-115.
116. Eisenstein EL, Newby LK, Knight JD, Shaw LJ, Califf RM, Topol EJ, Mark DB. Cost avoidance through early discharge of the uncomplicated acute myocardial infarction patient. J Am Coll Cardiol 330A;27.
117. Newby LK, Eisenstein EL, Califf RM, Thompson TD, Nelson CL, Peterson ED, Armstrong PW, Van de WF, White HD, Topol EJ, Mark DB. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 2000;342:749-755.
118. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, Grunwald MA, Levy D, Lytle BW, O’Rourke RA, Schafer WP, Williams SV, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A, Russell RO, Ryan TJ, Smith SC. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999;33:2092-2197.
119. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, Steward DE, Theroux P, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970-1062.
120. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith EE, Weaver WD, Gibbons RJ, Alpert JS, Eagle KA, Gardner TJ, Garson A, Gregoratos G, Smith SC. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100:1016-1030.
121. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Do '‘America’s Best Hospitals’' perform better for acute myocardial infarction? N Engl J Med 1999;340:286-292.
122. Ohman EM, Peterson E. Implications and challenges using practice guidelines for chronic angina. Ann Intern Med 2001;135:527-529.
123. CRUSADE investigation. http: //www.millenium.com/clinicians/cardiovascular/crusade/index. asp. Accessed, 2003.
124. Bradley EH, Holmboe ES, Mattera JA, Roumanis SA, Radford MJ, Krumholz HM. A qualitative study of increasing beta-blocker use after myocardial infarction: Why do some hospitals succeed? JAMA 2001;285:2604-2611.
125. Jamtvedt G, Young JM, Kristoffersen DT, Thomson O’Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev, 2003; CD000259.
126. Roe MT, Ohman EM, Pollack CV, Peterson ED, Brindis RG, Harrington RA, Christenson RH, Smith SC, Califf RM, Gibler WB. Changing the model of care for patients with acute coronary syndromes. Am Heart J 2003;146:605-612.
127. Chen V, Scott I. Systematic review of quality improvement interventions on inpatient management of acute coronary syndromes. Barcelona: XI Cochrane Colloquium, 2003.
128. National Health Expenditures. Health Care Financing Administration. In: www.hcfa.gov/stats/NHE-OAct./tables/t1.htm. Accessed March 07, 2000.
129. Hatziandreu EI, Koplan JP, Weinstein MC, Caspersen CJ, Warner KE. A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health 1988;78:1417-1421.
130. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990;113:852-871.
131. Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988;319:152-157.
132. Levin LA, Jonsson B. Cost-effectiveness of thrombolysis--a randomized study of intravenous rt-PA in suspected myocardial infarction. Eur Heart J 1992;13:2-8.
133. O’Brien BJ, Buxton MJ, Ferguson BA. Measuring the effectiveness of heart transplant programmes:quality of life data and their relationship to survival analysis. J Chronic Dis 1987; 40(suppl 1):137S-158S.